ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS SECONDARY TO IMATINIB IN A PATIENT WITH GASTROINTESTINAL STROMAL TUMOR
Youness Elkhachine
, Mohammed Sinaa
, Aziz Bazine
, Abdessamad Sakkah
, Abderazzak Jakar
and Jalal Elbenaye
- Department of Dermatology, Moulay Ismail Military Hospital, Meknes, Morocco.
- Department of Cytopathology, Moulay Ismail Military Hospital, Meknes, Morocco.
- Department of Oncology, Moulay Ismail Military Hospital, Meknes, Morocco.
- Abstract
- Keywords
- References
- Cite This Article as
- Corresponding Author
Background: Imatinib is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemias and gastrointestinal stromal tumors. Main Observation: We describe the case of a 64-year-old patient, who had been on imatinib 400 mg / day for a gastrointestinal stromal tumor. He developed one week later a diffuse pustular erythematous pruritic rash associated with an erosive cheilitis. The histological study confirmed the diagnosis of acute generalized exanthematous pustulosis (AGEP). Pharmacovigilance survey concluded that there is a causal link between imatinib and the occurrence of this cutaneous reaction. The causality assessment according to the updated French method was i5 and B3 for the intrinsic and extrinsic causality scores respectively. The evolution after discontinuation of this drug was favorable. The patient was then put on sunitinib with a complete therapeutic response and better tolerance. Conclusion: AGEP secondary to imatinib remains a rare but proven side effect. The outcome is generally favorable but requires the use of other molecules such as sunitinib.
- Pretel-Irazabal M, Tuneu-Valls A, Ormaechea-P?rez N. Efectos adversos cut?neos del imatinib (inhibidor de latiros?n cinasa). Actas Dermosifiliogr. 2014; 105(7):655-662.
- Dervis E, Ayer M, Akin Belli A, Barut SG. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A 6-year follow up. Eur J Dermatol. 2016; 26(2): 133-7.
- Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, Tulliez M, Giraudier S. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003;48(2) :201?206.
- Deslandres M, Sibaud V, Chevreau C, Delord JP. Effets secondaires cutan?s des nouvelles mol?cules anticanc?reuses : focus sur les mol?cules ciblant les r?cepteurs tyrosine kinase et le r?cepteur ? l?EGF. Ann dermatol venereal. 2008?; hors s?rie 1?: 16-24.
- Chun-Bing C, Ming-Ying W, Chau Yee N, Chun-Wei L and al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Management and Research. 2018; 10: 1259?1273.
- Scott, A. D., Lee, M., Kubba, F., & Chu, A. Acute generalized exanthematous pustulosis (AGEP) secondary to imatinib in a patient with chronic myeloid leukaemia. Clinical and Experimental Dermatology. 2014; 40(8): 926?927.
- Brouard MC; Prins C; Mach-Pascual S; Saurat JH. Acute Generalized Exanthematous Pustulosis Associated with STI571 in a Patient with Chronic Myeloid Leukemia. Dermatology 2001; 203:57-59.
- Schwarz M, Kreuzer KA, Baskaynak G, D?rken B, le Coutre P. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol. 2002 Oct; 69(4): 254-6.
- Miremont-Salam? G, Th?ophile H, Haramburu F and B?gaud B. Causality assessment in pharmacovigilance: The French method and its successive updates. Therapie. 2016; 71(2), 179?186.
[Youness Elkhachine, Mohammed Sinaa, Aziz Bazine, Abdessamad Sakkah, Abderazzak Jakar and Jalal Elbenaye (2020); ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS SECONDARY TO IMATINIB IN A PATIENT WITH GASTROINTESTINAL STROMAL TUMOR Int. J. of Adv. Res. 8 (Mar). 264-267] (ISSN 2320-5407). www.journalijar.com
Department of dermatology, Moulay Ismaïl military hospital, Meknes, Morocco
